Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
New immunotherapy combo shows 55% major pathologic response in high-risk melanoma, activating immune system
Meta-analysis reveals key risk factors for liver toxicity in cancer patients receiving immunotherapy
Meta-analysis shows ICI rechallenge may be safe and effective for some cancer patients who stopped treatment
Meta-analysis investigates sex-based differences in adverse events for cancer patients on immunotherapy
Phase III trial demonstrates efficacy and safety of pembrolizumab for advanced Merkel cell carcinoma.
Long-term study shows sustained benefits of adjuvant pembrolizumab in resected stage III melanoma.
Adjuvant pembrolizumab shows sustained benefits for stage IIB/IIC melanoma patients in phase III trial.